<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119447">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02038270</url>
  </required_header>
  <id_info>
    <org_study_id>Nexfin_002</org_study_id>
    <nct_id>NCT02038270</nct_id>
  </id_info>
  <brief_title>Accuracy of NexfinÂ® and NIBP to Predict IBP</brief_title>
  <official_title>Evolution of the Accuracy of the Nexfin Pressure Signal Compared to Invasive and Noninvasive Arterial Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Nexfin monitoring device relies on noninvasive pressure measurement using a finger-cuff
      manometer, combined with NIRS technology. The accuracy of the signal is dependent on the
      degree of vascular unloading, which takes an period before optimal unloading is reached. The
      evolution of the degree of inaccuracy caused by inclomplete unloading is quantified, and the
      absolute and relative inaccuracy of the nexfin as a function of the time is determined
      compared to the invasive blood pressure (IBP).

      Secondly, the accuracy of the Nexfin to predict the IBP is compared with the accuracy of
      noninvasive blood pressure to predict the IBP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients under stable anesthesia conditions, who have IBP and NIBP monitoring, the Nexfin
      will additionaly be connected. All data will be recorded for at least 30 minutes. NIBP will
      be measured every 5 minutes The evolution of the NIBP, IBP and Nexfin-derived blood pressure
      will be analysed to determine the evolution of inaccuracy due to incomplete vascular
      unloading and to determine the accuracy of Nexfin compared with NIBP to determine IBP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>vascular unloading time</measure>
    <time_frame>Start till end of operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>time to optimal vascular unloading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bloodpressure</measure>
    <time_frame>Start till end of operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>accuracy of nexfin compared to NIBP and IBP</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Bloodpressure</condition>
  <arm_group>
    <arm_group_label>surgical patients</arm_group_label>
    <description>120 Adult patients, that are having a routine surgical procedure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        120 Adult patients, that are having a routine surgical procedure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that are accepted for surgery

        Exclusion Criteria:

          -  Patients unable or unwilling to provide consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Kalmar, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>univertsity medical center groningen,university of groningen,the netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>May 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>MMRF Struys</investigator_full_name>
    <investigator_title>Prof dr</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
